Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17271864 | 0.87 | GPR119 (0.45) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL16993001 | 0.86 | EPHX1 (0.50) | GPR119EPHX1HPGDRECQLJAK2 | |
| SCHEMBL5195241 | 0.86 | EPHX1 (0.48) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL28891344 | 0.85 | GPR119 (0.43) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL13634197 | 0.85 | EPHX1 (0.48) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL15297469 | 0.85 | GPR119 (0.44) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL16105020 | 0.83 | EPHX1 (0.49) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL13811514 | 0.83 | GPR119 (0.52) | GPR119EPHX1HPGDRECQLJAK2 | |
| SCHEMBL2079844 | 0.82 | GPR119 (0.49) | GPR119EPHX1HPGDMEN1KMT2A | |
| SCHEMBL28983622 | 0.82 | KDM4E (0.42) | GPR119EPHX1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
| EP-2970340-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151958-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | GPR119 4035/4885EPHX1 1252/4885HPGD 657/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | GPR119 4035/4885EPHX1 1252/4885HPGD 657/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | GPR119 4035/4885EPHX1 1252/4885HPGD 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.